I TOLD YOU SO.
ATRS had no choice but to raise cash since they don't know if the FDA will approve the epi-pen. I dislike companies that raise cash at a lower share price then the previous raise. What a piece of junk.
Tomorrow or Friday is 60 days from filing the response to the CRL for Sumatriptan. The FDA normally responds within 60 days for a minor deficiency ANDA. The underwriters will use the volume to sell the additional 3 million shares. The recent shorting from $3 - $2.40 & the announcement is all planned ahead of time to get the secondary done.
Thats right. If they had news & FDA approval you wouldn't have the opportunity to get it at $2.10.
I listed SRPT as one of my two stock picks in the yearly challenge. I sold out of SRPT early in the year since I didn't like the way things were headed. I knew things had changed with the appointment of a new president but I kept looking for reasons to not invest. I missed out on a 65% gain today even though I knew it was going to move higher.
The same thing goes for ATRS. I know its going to move higher once they gain approval for the epi-pen. I can stand on the sidelines & look for reasons to not invest or I can follow my instincts.
The current response is to let looters burn down the city. Bunch of idiots.
I won't be surprised for it to trade down to $2 but we're only a month away from a possible approval for the epi-pen so its hard to not take a position. If the epi-pen is approved then its hard to believe ATRS is worth less then $4 a share.
Managements main goal is to keep the doors open. These guys have big salaries & they don't get a paycheck if they run out of cash. The shareprice is a secondary concern.
You've pretty much answered your own question. The .70 move is the cost that the underwriters need in order to find investors for a money losing speculative biotech.
The shareprices recent move is just a well orchestrated trade.
investors tout how great ATRS was & bash anyone who had a differing opinion. How come everyone of those guys have pretty much vanished from the board? The reason is that ATRS has continued to not meet their overly optimistic projections.
You guys complain about the posters on this board but you never contribute anything of value. The best thing would be to use another board or just quit the whining. Most of you lose money investing because your not willing to admit your weaknesses. I'm sure Andre deletes alot of his posts for the same reason I do & thats because he doesn't want to respond to the attacks. How come you guys don't attack LOKO for deleting his posts?
The reason I hang around is that some investors use this board to exchange investment ideas. Its not a very good stock to day trade so the board has never attracted the idiots you see on most yahoo boards.
I think it has to do with how investors feel mislead by the company & some investors.
A recent example is a post on Sumatriptan. "From the web site below - you will see this statement
about Sumatriptan to treat migraine: I assume it is valid, but wouldn't swear to it.
From the NovaDel Pharma Web site (a N. J. company developing a Sumatriptan spray for migraine) comes this quote: "With more than $1.2 billion in annual sales, sumatriptan is the leading migraine remedy".
So this is a sizable market and we have a 50 / 50 split with TEVA."
So a well respected poster gives information on the general market which sounds huge but why not supply information on the direct competitor in the market.
Zogenix sold Sumavel DosePro (Sumatriptan injector) to ENDP in April/2014 for $85 million plus up to $20 million in milestones . The drug does about $40 million in annual sales. ATRS investors should be using this as the comparator instead of the entire market. So if we used this as a way to value how much ATRS's injector is worth.
Zogenix sold 100% rights for $100 million so I'd guess ATRS's rights might be worth $25 million.
How much will the TEVA/ATRS Sumatriptan injector add to ATRS's revenues on a yearly basis? If the current market is $40 million & then its split equally with TEVA equals $20 million. ATRS receives half the net profits on sales so that might be $7.5 - $5 million a year which is quite a bit different from the $1.2 billion market.
Will you admit that Andre's report came from the JMP securities analyst?
Have you ever made a honest mistake?
If you say yes to these questions then it should be end of story?
I agree. You need to relax. You can't enjoy your profits from a hospital bed. We've probably got 3 more months before a decision.
Please explain how the shorts are giving away shares since they don't have shares to give away?
More then likely what's happening is someone's selling everyday & the short uses that weakness to cover?
"I can see anything that causes the slightest ripple in that progress to be upsetting to the
1. So you don't believe TEVA is pursuing MYLAN?
2. If TEVA purchased Mylan how would this effect ATRS?
clinical trials for QSM. Maybe they should consider finalizing the Phase III trial requirements for QST. They could even do something wild like issue a PR about signing up 3rd party payers for Otrexup.
I imagine ATRS will report Sumatriptan approval tomorrow but what some investors don't realize is that ATRS needs $50 - $100 million opportunities to move the needle when you have that many shares instead of $5 - $10 million from Suma.
I'm sure the stock will see a quick pop on the news but it will sell off.